Novavax, Inc (NASDAQ: NVAX) kicked off on Friday, up 11.43% from the previous trading day, before settling in for the closing price of $5.60. Over the past 52 weeks, NVAX has traded in a range of $3.81-$23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 516.28%. While this was happening, its average annual earnings per share was recorded 123.69%. With a float of $146.57 million, this company’s outstanding shares have now reached $160.42 million.
Let’s determine the extent of company efficiency that accounts for 952 employees. In terms of profitability, gross margin is 73.3%, operating margin of -35.6%, and the pretax margin is -25.89%.
Novavax, Inc (NVAX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Novavax, Inc is 8.87%, while institutional ownership is 59.78%. The most recent insider transaction that took place on Dec 13 ’24, was worth 37,435. In this transaction Director of this company sold 4,150 shares at a rate of $9.02, taking the stock ownership to the 14,770 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Director sold 5,400 for $8.00, making the entire transaction worth $43,200. This insider now owns 51,760 shares in total.
Novavax, Inc (NVAX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 123.69% per share during the next fiscal year.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Take a look at Novavax, Inc’s (NVAX) current performance indicators. Last quarter, stock had a quick ratio of 0.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach 0.59 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Looking closely at Novavax, Inc (NASDAQ: NVAX), its last 5-days average volume was 7.25 million, which is a jump from its year-to-date volume of 4.52 million. As of the previous 9 days, the stock’s Stochastic %D was 20.53%. Additionally, its Average True Range was 0.51.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 14.63%, which indicates a significant decrease from 30.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.95% in the past 14 days, which was lower than the 72.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.86, while its 200-day Moving Average is $10.36. However, in the short run, Novavax, Inc’s stock first resistance to watch stands at $6.60. Second resistance stands at $6.95. The third major resistance level sits at $7.59. If the price goes on to break the first support level at $5.61, it is likely to go to the next support level at $4.97. Now, if the price goes above the second support level, the third support stands at $4.62.
Novavax, Inc (NASDAQ: NVAX) Key Stats
The company with the Market Capitalisation of 1.00 billion has total of 160,844K Shares Outstanding. Its annual sales at the moment are 682,160 K in contrast with the sum of -187,500 K annual income. Company’s last quarter sales were recorded 88,310 K and last quarter income was -81,030 K.
